LifeMD(US:LFMD) Globenewswire·2025-10-07 18:21Core Viewpoint - LifeMD, Inc. is facing a class action lawsuit due to significant stock price decline following the company's revision of its 2025 revenue and adjusted EBITDA guidance, attributed to challenges in its Rex MD business [2][3]. Group 1: Company Performance - On August 5, 2025, LifeMD announced a revision of its full-year 2025 guidance for revenue and adjusted EBITDA, citing temporary challenges in its Rex MD business [2]. - Following this announcement, LifeMD's stock price dropped by $5.31, or 44.8%, closing at $6.53 per share on August 6, 2025, resulting in substantial losses for investors [2]. Group 2: Allegations in the Lawsuit - The class action complaint alleges that LifeMD's management made materially false and misleading statements regarding the company's business and prospects during the class period [3]. - Specific allegations include that the management overstated LifeMD's competitive position and failed to account for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs [3]. - The lawsuit claims that the positive statements made by the management lacked a reasonable basis and were materially misleading [3]. Group 3: Legal Proceedings - Investors who purchased LifeMD securities during the class period have until October 27, 2025, to file a lead plaintiff motion in the class action lawsuit [1][4].